FULGENT GENETICS, INC. Proceeds from Sale and Maturity of Marketable Securities
FULGENT GENETICS, INC. (FLGT) reported Proceeds from Sale and Maturity of Marketable Securities of $103.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-07-30
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $21.52M, a 64.28% decline year-over-year.
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $81.71M, a 151.84% increase year-over-year.
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $78.10M, a 8.79% increase year-over-year.
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $40.23M, a 65.88% decline year-over-year.
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2025 was $211.01M, a 39.68% decline from fiscal 2024.
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $349.80M, a 31.22% decline from fiscal 2023.
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $508.56M, a 118.70% increase from fiscal 2022.
- FULGENT GENETICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $232.53M, a 177.35% increase from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $103.23M 10-Q · filed 2026-07-30 | $181.32M derived: sum of 3 quarters · filed 2026-07-30 | $221.56M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $81.71M 10-Q · filed 2026-05-01 | $159.81M derived: sum of 2 quarters · filed 2026-05-01 | $200.04M derived: sum of 3 quarters · filed 2026-05-01 | $260.27M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $78.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $118.33M derived: sum of 2 quarters · filed 2026-02-27 | $178.56M derived: sum of 3 quarters · filed 2026-07-30 | $211.01M 10-K · filed 2026-02-27 |
| 2025-09-30 | $40.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $100.47M derived: sum of 2 quarters · filed 2026-07-30 | $132.91M 10-Q · filed 2025-11-07 | $204.70M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $60.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $92.67M 10-Q · filed 2026-07-30 | $164.46M derived: sum of 3 quarters · filed 2026-07-30 | $282.40M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $32.45M 10-Q · filed 2026-05-01 | $104.23M derived: sum of 2 quarters · filed 2026-05-01 | $222.17M derived: sum of 3 quarters · filed 2026-05-01 | $286.79M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $71.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $189.72M derived: sum of 2 quarters · filed 2026-02-27 | $254.34M derived: sum of 3 quarters · filed 2026-02-27 | $349.80M 10-K · filed 2026-02-27 |
| 2024-09-30 | $117.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $182.56M derived: sum of 2 quarters · filed 2025-11-07 | $278.01M 10-Q · filed 2025-11-07 | $409.68M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $64.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $160.07M 10-Q · filed 2025-08-01 | $291.74M derived: sum of 3 quarters · filed 2026-02-27 | $409.78M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $95.45M 10-Q · filed 2025-05-02 | $227.12M derived: sum of 2 quarters · filed 2026-02-27 | $345.16M derived: sum of 3 quarters · filed 2026-02-27 | $462.60M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $131.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $249.71M derived: sum of 2 quarters · filed 2026-02-27 | $367.15M derived: sum of 3 quarters · filed 2026-02-27 | $508.56M 10-K · filed 2026-02-27 |
| 2023-09-30 | $118.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $235.48M derived: sum of 2 quarters · filed 2024-11-08 | $376.89M 10-Q · filed 2024-11-08 | $477.71M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $117.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $258.85M 10-Q · filed 2024-08-02 | $359.67M derived: sum of 3 quarters · filed 2025-02-28 | $420.95M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $141.41M 10-Q · filed 2024-05-03 | $242.23M derived: sum of 2 quarters · filed 2025-02-28 | $303.51M derived: sum of 3 quarters · filed 2025-02-28 | $346.18M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $100.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $162.10M derived: sum of 2 quarters · filed 2025-02-28 | $204.77M derived: sum of 3 quarters · filed 2025-02-28 | $232.53M 10-K · filed 2025-02-28 |
| 2022-09-30 | $61.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $103.95M derived: sum of 2 quarters · filed 2023-11-03 | $131.71M 10-Q · filed 2023-11-03 | $154.04M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $42.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $70.43M 10-Q · filed 2023-08-04 | $92.76M derived: sum of 3 quarters · filed 2024-02-28 | $119.74M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $27.76M 10-Q · filed 2023-05-05 | $50.09M derived: sum of 2 quarters · filed 2024-02-28 | $77.06M derived: sum of 3 quarters · filed 2024-02-28 | $97.14M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $22.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $49.30M derived: sum of 2 quarters · filed 2024-02-28 | $69.38M derived: sum of 3 quarters · filed 2024-02-28 | $83.84M 10-K · filed 2024-02-28 |
| 2021-09-30 | $26.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $47.06M derived: sum of 2 quarters · filed 2022-11-07 | $61.52M 10-Q · filed 2022-11-07 | $68.32M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $20.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $34.54M 10-Q · filed 2022-08-04 | $41.34M derived: sum of 3 quarters · filed 2023-02-28 | $47.13M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $14.46M 10-Q · filed 2022-05-05 | $21.26M derived: sum of 2 quarters · filed 2023-02-28 | $27.05M derived: sum of 3 quarters · filed 2023-02-28 | $29.45M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $12.59M derived: sum of 2 quarters · filed 2023-02-28 | $14.99M derived: sum of 3 quarters · filed 2023-02-28 | $19.92M 10-K · filed 2023-02-28 |
| 2020-09-30 | $5.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $8.19M derived: sum of 2 quarters · filed 2021-11-09 | $13.12M 10-Q · filed 2021-11-09 | $17.87M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $7.33M 10-Q · filed 2021-08-10 | $12.08M derived: sum of 3 quarters · filed 2022-02-28 | $20.18M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $4.93M 10-Q · filed 2021-05-07 | $9.68M derived: sum of 2 quarters · filed 2022-02-28 | $17.78M derived: sum of 3 quarters · filed 2022-02-28 | $25.68M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $12.85M derived: sum of 2 quarters · filed 2022-02-28 | $20.75M derived: sum of 3 quarters · filed 2022-02-28 | $24.35M 10-K · filed 2022-02-28 |
| 2019-09-30 | $8.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $16.00M derived: sum of 2 quarters · filed 2020-08-05 | $19.60M 10-Q · filed 2019-11-08 | $28.21M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-06-30 | $7.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $11.50M 10-Q · filed 2020-08-05 | $20.11M derived: sum of 3 quarters · filed 2020-08-05 | $27.81M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $3.60M 10-Q · filed 2020-05-06 | $12.21M derived: sum of 2 quarters · filed 2020-05-06 | $19.91M derived: sum of 3 quarters · filed 2020-05-06 | $25.72M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $8.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $16.31M derived: sum of 2 quarters · filed 2020-03-13 | $22.12M derived: sum of 3 quarters · filed 2020-03-13 | $27.97M 10-K · filed 2020-03-13 |
| 2018-09-30 | $7.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $13.51M derived: sum of 2 quarters · filed 2019-11-08 | $19.36M 10-Q · filed 2019-11-08 | $25.14M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $11.66M 10-Q · filed 2019-08-12 | $17.44M derived: sum of 3 quarters · filed 2019-08-12 | $19.24M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $5.85M 10-Q · filed 2019-05-10 | $11.63M derived: sum of 2 quarters · filed 2019-05-10 | $13.44M derived: sum of 3 quarters · filed 2019-05-10 | $16.04M derived: sum of 4 quarters · filed 2019-05-10 |
| 2017-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $7.58M derived: sum of 2 quarters · filed 2019-03-22 | $10.19M derived: sum of 3 quarters · filed 2019-03-22 | $11.19M 10-K · filed 2019-03-22 |
| 2017-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $4.40M derived: sum of 2 quarters · filed 2018-11-09 | $5.40M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $3.60M 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $1.00M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |